Experimental HIV Vaccine Regimen Safe but Ineffective

January 18, 2023 by Dan McCue
Experimental HIV Vaccine Regimen Safe but Ineffective
Transmission electron micrograph of HIV-1 virus particles (red) budding and replicating from a segment of a chronically infected H9 cell (blue). (NIAID photo)

WASHINGTON — An investigational HIV vaccine regimen tested among men who have sex with men and transgender people was safe but did not provide protection against HIV acquisition, an independent monitoring board has determined. 

The Phase 3 clinical trial for HPX3002/HVTN 706, or “Mosaico,” began in 2019 and involved 3,900 volunteers ages 18 to 60 years in Europe, North America and South America. 

Janssen Vaccines & Prevention B.V., sponsored the study with funding support from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. 

Based on the monitoring board’s recommendation, the study will be discontinued. Participants are being notified of the findings, and further analyses of the study data are planned.


The experimental vaccine regimen was developed by Janssen. It was based on “mosaic” immunogens — vaccine components featuring elements of multiple HIV subtypes — with the goal of inducing immune responses against a wide variety of global HIV strains. 

The investigational vaccine regimen consisted of four injections over a year of Ad26.Mos4.HIV. 

This vaccine candidate uses a common-cold virus (adenovirus serotype 26, or Ad26) to deliver the mosaic immunogens. 


The final two vaccinations were accompanied by a bivalent (two-component) HIV envelope protein formulation, combining clade C gp140 and mosaic gp140 envelope proteins, adjuvanted by aluminum phosphate to boost immune responses. All study vaccinations were completed in October 2022.

In its scheduled data review, the monitoring board determined there were no safety issues with the experimental vaccine regimen. 

However, the number of HIV infections were equivalent between the vaccine and placebo arms of the study. 

During the clinical trial, all participants were offered comprehensive HIV prevention tools, including pre-exposure prophylaxis, or PrEP.

Study staff ensured that participants who acquired HIV during the trial were promptly referred for medical care and treatment.

The Mosaico findings track with developments in the Phase 2b “Imbokodo” (HPX2008/HVTN 705) clinical trial, which was testing a similar HIV vaccine regimen in young women in sub-Saharan Africa. 


A monitoring board determined in 2021 that the experimental vaccine regimen in that study was also safe but ineffective in protecting against HIV acquisition.

Dan can be reached at [email protected] and at https://twitter.com/DanMcCue

A+
a-

In The News

Health

Voting

Health

March 31, 2023
by Dan McCue
EPA, Justice Dept. Seek Civil Penalties In East Palestine Wreck

WASHINGTON — The Environmental Protection Agency, in coordination with the U.S. Justice Department, is seeking potentially millions of dollars in... Read More

WASHINGTON — The Environmental Protection Agency, in coordination with the U.S. Justice Department, is seeking potentially millions of dollars in civil fines from the Norfolk Southern Railway Co. in connection to the Feb. 3 derailment of a train carrying hazardous materials near East Palestine, Ohio. In... Read More

March 31, 2023
by Kate Michael
Analysts Blame Farm Runoff for Toxic Algae Blooms

WASHINGTON — Americans starting to think about spring and summer vacations as the weather warms may find their favorite water... Read More

WASHINGTON — Americans starting to think about spring and summer vacations as the weather warms may find their favorite water destinations unsafe for swimming. Thick layers of cyanobacteria — commonly known as blue-green algae — have closed popular local lakes in recent years, and Florida has... Read More

Transgender Visibility Saves Lives in the Clinic, Too

The overwhelming evidence and consensus among global health organizations is that gender-affirming care saves lives. Yet many transgender, nonbinary and... Read More

The overwhelming evidence and consensus among global health organizations is that gender-affirming care saves lives. Yet many transgender, nonbinary and gender non-conforming people lack access to the care they need. Some must wait up to a year to talk to a medical professional about gender-affirming care.... Read More

March 29, 2023
by Dan McCue
Increased Telehealth Use Reduced Overdose Risk During Pandemic

WASHINGTON — An increased reliance on telehealth services and medications for opioid use disorder by Medicare beneficiaries significantly reduced their... Read More

WASHINGTON — An increased reliance on telehealth services and medications for opioid use disorder by Medicare beneficiaries significantly reduced their risk for fatal overdoses during the COVID-19 pandemic, the National Center for Injury Prevention and Control reported on Wednesday. Published in JAMA Psychiatry, the study is... Read More

Fundraising Over Solutions: Women’s Health and a Missed Opportunity Post-Dobbs

In June 2022 the U.S. Supreme Court issued a decision that provided the sought after political fodder to catapult fundraising... Read More

In June 2022 the U.S. Supreme Court issued a decision that provided the sought after political fodder to catapult fundraising efforts heading into the 2022 midterm election cycle. In the June opinion, the court overruled two cases from 1973 and 1992, and returned the matter of... Read More

March 29, 2023
by Dan McCue
Budzinski Joins Overdose, Addiction Working Groups

WASHINGTON — Rep. Nikki Budzinski, D-Ill., has joined the Bipartisan Fentanyl Prevention Caucus and the Bipartisan Mental Health and Substance... Read More

WASHINGTON — Rep. Nikki Budzinski, D-Ill., has joined the Bipartisan Fentanyl Prevention Caucus and the Bipartisan Mental Health and Substance Use Disorder Task Force where, she says, she will work across the aisle on solutions to the ongoing addiction crisis.  “Every day, too many of our... Read More

News From The Well
scroll top